Plasma biomarkers for predicting heart failure in patients with acute myocardial infarction

血浆生物标志物在预测急性心肌梗死患者心力衰竭中的应用

阅读:1

Abstract

BACKGROUND: Heart failure (HF) following acute myocardial infarction (AMI) is characterized by high mortality and disability rates, which highlights the need of timely and effective revascularization. Recent studies suggested the potential predictivity of biomarkers NT-proBNP, cTNT, PLR, NLR, and GDF-15 in cardiovascular events, but their value in HF patients post-AMI still require further verification. Therefore, the present study aimed to identify potent biomarkers for prognosticating the development of HF subsequent to AMI, and to devise early interception and therapeutic strategies. METHODS: A total of 170 patients with AMI were enrolled in this study, including 44 patients with post-AMI HF and 126 patients with post-AMI non-HF. We measured the serum biomarkers NT-proBNP, cTNT, PLR, NLR, and GDF-15 in all patients using enzyme-linked immunosorbent assay (ELISA). Subsequently, we performed t-tests to assess the predictive value of these biomarkers for post-AMI HF. RESULTS: In the group of HF patients, cTNT, NT-proBNP, GDF-15 and NLR was significantly higher than in the group without HF, but PLR was not. The AUC of NLR to predict HF after AMI was 0.632 (95%CI: 0.542-0.723), P=0.010, with a cut-off value of (3.86×109)/L, GDF-15 was 0.661 (95%CI: 0.560-0.763), P=0.002, with a cutoff value of 1.35 ng/mL, and NT-proBNP was 0.82 (95%CI: 0.723-0.876), P<0.001, with a cut-off value of 1444 pg/mL. CONCLUSIONS: In five biomarkers, there is predictive value in NT-proBNP, NLR, GDF-15 for patients with HF after AMI.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。